Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2017; 17(4):258-261
DOI: 10.5428/pcar20170405
Case analysis of alternative non-heparin anticoagulant treatment for heparin-induced thrombocytopenia
1. HUANG JingJing1(1.Department of Pharmacy,Ruijin Hospital Affiliated to Medical School of Shanghai Jiaotong University,Shanghai 200025,China [email protected])
2. HUANG WeiFeng2( 2.Department of Intensive Care Unit,Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200233,China )
3. CHEN Yan3(3.Department of Pharmacy, Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200233,China [email protected])
ABSTRACT  Objective: Heparin-induced thrombocytopenia (HIT) is a severe immune adverse reaction to heparin (both unfractionated and low-molecular-weight).The case was analyzed to provide reference for HIT treatment in critically ill patients.Methods: The clinical pharmacist was involved in the HIT treatment of a critically ill patient with severe abdominal infection by using pharmaceutical knowledge and evidence-based literature.The individualized anticoagulant regimen for the patient was designed,with close pharmaceutical rounds.Results: After 2 weeks of alternative treatment,the platelet counts of the patient returned to the value before the occurrence of HIT and oral warfarin was finally adopted.Conclusion: Through the application of professional knowledge,clinical pharmacist involvement in the first-line diagnosis and treatment and provision of good pharmaceutical care was one of the effective methods in the transformation of pharmaceutical care.
Welcome to PCAR! You are the number 546 reader of this article!
Please cite this article as:
HUANG JingJing1,HUANG WeiFeng2,CHEN Yan3,. Case analysis of alternative non-heparin anticoagulant treatment for heparin-induced thrombocytopenia[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(4): 258-261.
1. Salter B S,Weiner M M,Trinh M A,et al.Heparin-induced thrombocytopenia: a comprehensive clinical review[J].J Am Coll Cardiol,2016,67(21):2519-2532.
2. Cosmi B.Current management of heparin-induced thrombocytopenia[J].Expert Rev Hematol,2015,8(6):837-849.
3. Severe Medical Branch of Chinese Medical Association.Prevention guidelines for deep vein thrombosis in the patients of ICU[J].Chin J Pract Surg,2009,29(10):793-797.In Chinese.
4. Expert Consensus Group on Clinical Application of Procalcitonin in Emergency.Expert consensus on the clinical application of procalcitonin (PCT) in emergency[J].Chin J Emerg Med,2012,21(9):944-951.In Chinese.
5. LI Ying,HU YongFang,PENG FangChen.Evidence-based analysis of thrombocytopenia caused by cefoperazone/sulbactam[J].Chin Pharm J,2009,44(23):1938-1941.In Chinese with English abstract.
6. Cuker A,Gimotty P A,Crowther M A,et al.Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis[J].Blood,2012,120(20):4160-4167.
7. Cuker A,Crowther M A.2013 clinical practice guidelines on the evaluation and management of adults with suspected heparin-induced thrombocytopenia (HIT)[EB/OL].(2013-09-18)[2016-11-12].
8. Kelton J G.The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment[J].Chest,2005,127(2 Suppl):9S-20S.
9. Lewis B E,Wallis D E,Hursting M J,et al.Effects of argatroban therapy,demographic variables,and platelet count on thrombotic risks in heparin-induced thrombocytopenia[J].Chest,2006,129(6):1407-1416.
10. Warkentin T E,Greinacher A.Management of heparin-induced thrombocytopenia[J].Curr Opin Hematol,2016,23(5):462-470.
11. XU JunTang.The clinical application of argatroban[J].Chin J Thromb Hemost,2007,12(4):180-182.In Chinese.
12. Keyl C,Zimmer E,Bek M J,et al.Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia[J].Thromb Haemost,2016,115(6):1081-1089.
13. SHEN YuJing,YANG YueJin.The diagnosis and treatment of heparin-induced thrombocytopenia[J].Chin J Cardiol,2009,37(4):381-384.In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:[email protected]